BioSpace News Archive

Business

ICON plc Schedules Third Quarter 2022 Earnings Conference Call

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the third quarter 2022 after the market closes on Wednesday, November 2, 2022.

September 26, 2022
·
2 min read
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile

Zymeworks Inc. is pleased to announce that a second independent proxy advisory firm, Institutional Shareholder Services Inc., has recommended shareholders vote FOR the Company’s plan to become a Delaware corporation.

September 26, 2022
·
9 min read
Pharm Country

AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million

AnPac Bio-Medical Science Co., Ltd. announced that on September 26, 2022, the Company and a group of nine institutional and individual investors have signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 Million.

September 26, 2022
·
5 min read
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip’ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules, announced today its plans to focus on treating CNS disorders.

September 26, 2022
·
6 min read
BioIVT Acquires Fidelis Research

This transaction increases BioIVT’s global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.

September 26, 2022
·
4 min read
Pharm Country

New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more vulnerable populations such as children.

September 26, 2022
·
11 min read
Pharm Country

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.

September 26, 2022
·
16 min read
Biotech Beach

Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4.

September 26, 2022
·
2 min read
Pharm Country

Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

Outlook Therapeutics, Inc. today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.

September 26, 2022
·
2 min read
Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements

Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive 6-month results from an ongoing clinical study conducted in Poland under a hospital exemption protocol of DT-DEC01, the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).

September 26, 2022
·
4 min read